Abstract
An extensive series of evaluations have been performed as part of an IAEA coordinated research project to study a set of nuclear reactions that produce the diagnostic gamma-ray emitting radionuclides 51Cr, 99mTc, 111In, 123I and 201Tl. Recommended cross-section data in the form of excitation functions have been derived, along with quantifications of their uncertainties. These evaluations involved the compilation of all previously published values and newly measured experimental data, followed by critical assessments and selection of those experimental datasets and accompanying uncertainties judged to be fully valid and statistically consistent for model-independent least-squares fitting by means of Padé approximations. Integral yields as a function of the energy were also calculated on the basis of the recommended cross sections deduced from these various fits. All evaluated numerical results and their corresponding uncertainties are available online at www-nds.iaea.org/medical/gamma_emitters.html and also on the medical portal of the International Atomic Energy Agency/Nuclear Data Section (IAEA-NDS) www-nds.iaea.org/medportal/.
Highlights
The production of diagnostic and therapeutic radionuclides for medical applications is a very important non-energy related application of nuclear science and technology [1]
An extensive series of evaluations have been performed as part of an International Atomic Energy Agency (IAEA) coordinated research project to study a set of nuclear reactions that produce the diagnostic gamma-ray emitting radionuclides 51Cr, 99mTc, 111In, 123I and 201Tl
Such radionuclides are produced in both neutron and charged-particle induced nuclear reactions, and the list of these reactions used for the generation of diagnostic radioisotopes and employed to monitor these preparative procedures is long
Summary
The production of diagnostic and therapeutic radionuclides for medical applications is a very important non-energy related application of nuclear science and technology [1]. Dedicated compilations and evaluations of production cross-section data for such medical radionuclides were started over 20 years ago in a Coordinated Research Project (CRP) initiated and supported by the International Atomic Energy Agency (IAEA) [2]. This first concerted effort was identified with nuclear reactions used to produce widely used diagnostic radionuclides for SPECT and PET imaging (twenty-six reactions to generate 11C, 13N, 15O, 18F, 67Ga, 68Ge/68Ga, 81Rb, 82Sr, 111In, 123I, 123Cs/123Xe/123I and 201Pb/201Tl), and a selection of twenty-two reactions used to monitor beam parameters during the irradiations. A second IAEA CRP was launched in 2003 to cover the production routes for established (103Pd, 186Re and 192Ir) and emerging therapeutic radionuclides (64Cu, 67Cu, 67Ga, 86Y, 111In, 114mIn, 124I, 125I, 169Yb, 177Lu, 211At and 225Ac) totalling thirty-five reactions [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
